Loading stock data…
EVGN
$0.60+0.01 (+2.40%)
After Hours$0.60-0.00 (-0.02%)· Last close Jun 9
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Evogene Ltd. in the Healthcare sector is trading at $0.60 with a market capitalization of $6M. Wall Street consensus targets $2.15 (1 analysts), implying a +260.1% move over the next 12 months. The stock is currently near its 52-week low of $0.52, remaining 40.9% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 27 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +260.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 27) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$0.60
Potential Downside
0%
Whystock Fair Value$0.60
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engage...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.22M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.74
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
333.36%
Volume
Today's trading volume
311,160
Recent News
Evogene Ltd (EVGN) Q1 2026 Earnings Call Highlights: Strategic Collaborations Amid Financial ...
Despite a significant net loss and revenue decline, Evogene Ltd (EVGN) focuses on strategic partnerships and technological advancements to drive future growth.
Evogene Ltd. Q1 2026 Earnings Call Summary
Moby summary of Evogene Ltd.'s Q1 2026 earnings call
Evogene Shares Decline After Revenue Miss Despite Stronger-Than-Expected Earnings (EVGN)
Evogene Ltd. (NASDAQ:EVGN) reported first-quarter results on Wednesday that exceeded earnings expectations but missed analyst revenue forecasts.
Evogene Ltd (EVGN) Q4 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue Decline
Despite a drop in revenue, Evogene Ltd (EVGN) focuses on AI-driven innovations and strategic partnerships to enhance future growth prospects.
Evogene Ltd. Q4 2025 Earnings Call Summary
Moby summary of Evogene Ltd.'s Q4 2025 earnings call